hackint0sh/New-Dataset huggingface dataset:
nctId: NCT06283368 id: 2021/11-06 briefTitle: Red Blood Cell Distributions (RDW, RDW-CW) and Lymphocyte Monocyte Ratios (LMR) for the Malignant Thyroid Nodules overallStatus: COMPLETED date: 2016-01 date: 2021-01 date: 2021-01 date: 2024-02-28 date: 2024-03-01 name: Kahramanmaras Sutcu Imam University class: OTHER briefSummary: Thyroid surgery is the most common type of surgery among endocrine surgeries. This surgery is performed for patients with suspected malignancy, patients diagnosed with malignancy, and toxic nodular goiter. In addition to vocal cord injury, which is the most important complication of thyroid surgery, hypocalcemia due to hypoparathyroidism and surgical wound complications (such as hematoma, and fistula) can also be observed, and malignancy surgery increases the risk of recurrent laryngeal nerve injury. Therefore, it is important to differentiate these groups using non-invasive methods before surgery.
Our aim in this study is to reveal the RDW, RDW-CW, and LMR calculated from complete blood count parameters in the preoperative period, as an indicator of malignant inflammatory response, in a non-invasive and inexpensive way before surgery or biopsy is performed to distinguish nodular goiter and thyroid malignancy. conditions: Thyroid Neoplasms Benign conditions: Thyroid Nodule conditions: Thyroid Cancer conditions: Thyroid Diseases studyType: OBSERVATIONAL observationalModel: CASE_CONTROL timePerspective: RETROSPECTIVE count: 172 type: ACTUAL name: Thyroidectomy, Bilaterally Total name: Thyroidectomy, Unilaterally Total name: Thyroidectomy, Complementary name: Thyroidectomy, Near Total measure: Determining benign thyroid nodules measure: Determining malignant thyroid nodules sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06283355 id: IRB00433691 briefTitle: Comparing Single Versus Repeat NMT on the Diversity of the Neonatal Nasal Microbiome overallStatus: NOT_YET_RECRUITING date: 2024-05-15 date: 2025-06-01 date: 2025-12-31 date: 2024-02-28 date: 2024-02-28 name: Johns Hopkins University class: OTHER briefSummary: This study aims to determine whether a parent-to-child nasal microbiota transplant (NMT) can seed and engraft parental organisms into the neonatal microbiome and increase the neonatal microbiome diversity. conditions: Staphylococcus Aureus conditions: Microbial Colonization conditions: Neonatal Infection studyType: INTERVENTIONAL phases: PHASE1 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: PREVENTION masking: NONE count: 175 type: ESTIMATED name: Nasal Microbiota Transplant (NMT) name: Placebo measure: Neonatal nasal microbiome diversity after intervention sex: ALL minimumAge: 0 Years maximumAge: 60 Years stdAges: CHILD stdAges: ADULT facility: Johns Hopkins University city: Baltimore state: Maryland zip: 21287 country: United States name: Danielle Koontz role: CONTACT phone: 443-287-9040 email: dkoontz1@jhmi.edu name: Aaron Milstone role: PRINCIPAL_INVESTIGATOR lat: 39.29038 lon: -76.61219 hasResults: False
nctId: NCT06283342 id: Konya Pediatric Hematology briefTitle: Prophylactic Iron and Nutrition in Preventing Infant Iron Deficiency overallStatus: COMPLETED date: 2018-01-01 date: 2019-01-01 date: 2019-02-01 date: 2024-02-28 date: 2024-02-28 name: Konya Meram State Hospital class: OTHER briefSummary: This study aimed to reveal the effects of prophylactic iron preparations, adequate breast milk intake, and iron-rich supplementary food intake in the prevention of IDA (iron deficiency anemia) and ID (iron deficiency) in infancy. conditions: Iron Deficiency Anemia in Childbirth conditions: Infant Nutrition Disorders conditions: Iron Deficiencies studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 2 type: ACTUAL measure: Ferritine level measure: Hemoglobin level measure: Prophylactic iron use rate measure: Iron-sufficient supplementary food intake rate of babies measure: Breast milk usage rate sex: ALL minimumAge: 6 Months maximumAge: 24 Months stdAges: CHILD facility: Konya Training and Research Hospital city: Konya zip: 42090 country: Turkey lat: 37.87135 lon: 32.48464 hasResults: False
nctId: NCT06283329 id: echographic VC curarization briefTitle: Residual Vocal Cords Curarization Correlation Between Clinical and Ultrasound Endpoints overallStatus: COMPLETED date: 2023-12-01 date: 2023-12-31 date: 2023-12-31 date: 2024-02-28 date: 2024-02-28 name: General Administration of Military Health, Tunisia class: NETWORK briefSummary: Through recent studies residual curarization (RC) remains frequent but serious event, that could be easily avoided in the presence of a paraclinical monitoring and by antagonization of curares. However, conventional monitors focus only on peripheral muscles, whereas ultrasonography allows direct visualization of laryngeal muscles, particularly the vocal cords, which are directly influenced by neuromuscular blocking agents. The aim of the study was to evaluate the ultrasound mobility of the vocal cords after awakening and extubation of general anesthesia compared to their preoperative mobility and its correlation with clinical and paraclinical diagnostic criteria (DG) for RC. conditions: Residual Curarization studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 70 type: ACTUAL name: vocal cords echography measure: Echographic mobility of vocal cords at different times in post extubation sex: ALL minimumAge: 18 Years maximumAge: 70 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Elaskri Haythem city: Tunis zip: 1008 country: Tunisia lat: 36.81897 lon: 10.16579 hasResults: False
nctId: NCT06283316 id: 11347 briefTitle: Systemic Treatments for Alopecia Areata Registry acronym: STA2R overallStatus: RECRUITING date: 2024-01-17 date: 2099-12-31 date: 2099-12-31 date: 2024-02-28 date: 2024-02-28 name: Erasmus Medical Center class: OTHER briefSummary: A multicenter prospective registry (STA2R) is conducted to assess systemic treatments for alopecia areata, focusing on effectiveness, safety, and long-term outcomes. conditions: Alopecia Areata conditions: Alopecia Totalis conditions: Alopecia Universalis conditions: Hair Loss conditions: Hair Diseases conditions: Alopecia conditions: Alopecia Drugs conditions: Autoimmune Diseases studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 10000 type: ESTIMATED measure: Effectiveness of systemic treatments measure: Safety of systemic treatments measure: Epidemiological data measure: Physician Reported - Severity of Alopecia Tool (SALT Score) measure: Dermatology Life Quality Index (DLQI, 10 items) measure: Alopecia Areata Symptom Impact Scale (AASIS, 13 items) sex: ALL minimumAge: 16 Years stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT facility: Erasmus University Medical Center status: RECRUITING city: Rotterdam country: Netherlands name: DirkJan Hijnen, MD, PhD role: CONTACT phone: 0031 10 704 01 10 email: d.hijnen@erasmusmc.nl lat: 51.9225 lon: 4.47917 hasResults: False
nctId: NCT06283303 id: MVR-T3011-HAI-01 briefTitle: A Clinical Study of T3011 in Combination With Toripalimab and Regorafenib in Patients With Colorectal Cancer overallStatus: NOT_YET_RECRUITING date: 2024-04-02 date: 2025-11-30 date: 2025-11-30 date: 2024-02-28 date: 2024-02-29 name: China Medical University, China class: OTHER name: Immvira Co., Limited briefSummary: This is a phase I, open-label clinical study of T3011 in combination with Toraplizumab and Regorafenib in patients with liver metastases from colorectal cancer. conditions: Colorectal Cancer Metastatic studyType: INTERVENTIONAL phases: PHASE1 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 8 type: ESTIMATED name: T3011 hepatic artery infusion name: toripalimab name: regorafenib measure: Treatment Emergent Adverse Event（TEAE） measure: Objective response rate (ORR) measure: Overall survival (OS) measure: Progression-free survival (PFS) sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06283290 id: D3250R00122 briefTitle: PROPE Severe Asthma Study in Egypt overallStatus: RECRUITING date: 2024-03-12 date: 2024-07-31 date: 2024-07-31 date: 2024-02-28 date: 2024-04-19 name: AstraZeneca class: INDUSTRY briefSummary: Asthma is a syndrome characterized by airway inflammation, reversible airway obstruction, and airway hyper-responsiveness. Patients present clinically with recurrent wheezing, shortness of breath, cough, and chest tightness. Asthma is a leading cause of morbidity with a global prevalence of approximately 300 million; it is estimated that the number of people with asthma may increase to 400 to 450 million people worldwide by 2025.
Severe asthma is not considered a single disease; instead, it is divided into several phenotypes, owing to the variety of inflammatory, clinical, and functional characteristics that it can present with. One of the proposed and most studied phenotypes is severe eosinophilic asthma. Patients with severe asthma that is accompanied by a high concentration of eosinophils require greater healthcare resource use, greater disease management costs, and a much more impaired QoL than those who do not present with raised eosinophilia.
This cross-sectional, multicenter study aims to determine the prevalence of oral corticosteroid (OCS) use among severe asthma patients who attend to different sites specialized in the management of severe asthma across Egypt. In addition, the prevalence of eosinophilic phenotype of blood eosinophil count ≥ 150 cells/mm3, prevalence of atopic phenotype, and asthma control will also be studied. conditions: Severe Asthma studyType: OBSERVATIONAL observationalModel: OTHER timePerspective: CROSS_SECTIONAL count: 150 type: ESTIMATED measure: To describe the prevalence (frequency) of OCS use among severe asthma patients as defined by chronic treatment and/or bursts of OCS use. measure: To describe the demographic characteristics of severe eosinophilic asthma patients. measure: To describe the clinical characteristics of severe eosinophilic asthma patients. measure: To discover the average OCS dose per year used among severe asthma patients. measure: To determine the prevalence of the eosinophilic phenotype measure: To determine the prevalence of the eosinophilic phenotype measure: To determine the prevalence of the total serum IgE measure: To determine the annual severe asthma exacerbation rate in the past twelve months among severe asthma patients in Egypt measure: To evaluate asthma control of severe asthma patients measure: To evaluate comorbidities related to OCS use sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Research Site status: NOT_YET_RECRUITING city: Mansoura state: Dakahlia country: Egypt lat: 31.03637 lon: 31.38069 facility: Research Site status: RECRUITING city: Zagazig state: Sharkia country: Egypt lat: 30.58768 lon: 31.502 facility: Research Site status: RECRUITING city: Alexandria country: Egypt lat: 31.21564 lon: 29.95527 facility: Research Site status: RECRUITING city: Cairo country: Egypt lat: 30.06263 lon: 31.24967 facility: Research Site status: NOT_YET_RECRUITING city: Cairo country: Egypt lat: 30.06263 lon: 31.24967 hasResults: False
nctId: NCT06283277 id: fetal macrosomia briefTitle: Fetal Clavicular Measurement to Predict Fetal Macrosomia overallStatus: NOT_YET_RECRUITING date: 2024-05-01 date: 2027-04-30 date: 2027-10-30 date: 2024-02-28 date: 2024-02-28 name: Assiut University class: OTHER briefSummary: Macrosomia is associated with increased risks for both the mother and the baby, including complications during delivery, injuries, and even death. The accurate diagnosis of macrosomia is often difficult before birth. There are a number of factors that can increase the risk of macrosomia, such as maternal obesity, diabetes, and excessive weight gain during pregnancy. There are also a number of different techniques that can be used to try to predict macrosomia, but none of them are perfect.
The aim of this study is to evaluate sensitivity of measuring fetal clavicle length in third trimester compared with biacromial diameter and Hadlock formula IV for prediction of fetal macrosomia. conditions: Macrosomia, Fetal conditions: Large for Gestational Age conditions: Shoulder Dystocia studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: CROSS_SECTIONAL count: 240 type: ESTIMATED name: Obstetric Ultrasound measure: Third trimester clavicle length measurement measure: Establish the relationship between third-trimester clavicle length and shoulder dystocia measure: Mode of delivery measure: Gestational age at the time of delivery. measure: Neonatal Apgar score. measure: Neonatal bi-acromial diameter measure: Neonatal birth weight measure: Neonatal need for NICU measure: Neonatal actual clavicle length sex: FEMALE minimumAge: 18 Years maximumAge: 45 Years stdAges: ADULT hasResults: False
nctId: NCT06283264 id: Coeliac Disease in type2 DM briefTitle: Assessment of Coeliac Disease in Patients With Type 2 Diabetes overallStatus: NOT_YET_RECRUITING date: 2024-03-15 date: 2026-12-01 date: 2026-12-30 date: 2024-02-28 date: 2024-02-28 name: Assiut University class: OTHER briefSummary: This study aims to screen and diagnose coeliac disease in patients with type 2 diabetes and monitor the effect of gluten-free diet on the metabolic status conditions: Celiac Disease studyType: OBSERVATIONAL observationalModel: OTHER timePerspective: CROSS_SECTIONAL count: 100 type: ESTIMATED measure: 1-Prevalence of coeliac disease among diabetic type 2 patient 2-its effect on glycemic control sex: ALL minimumAge: 18 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06283251 id: 23-590 briefTitle: PediRISE Feasibility overallStatus: NOT_YET_RECRUITING date: 2024-06 date: 2024-12-31 date: 2024-12-31 date: 2024-02-28 date: 2024-02-28 name: Dana-Farber Cancer Institute class: OTHER name: American Cancer Society, Inc. name: Children's Cancer Research Fund briefSummary: The goal of this research study is to learn whether investigators can successfully give the PediRISE program to families-in other words, whether most families are interested in participating in a study about the PediRISE program, including a 50-50 chance of receiving standard usual care, and a 50-50 chance of receiving the PediRISE support program.
* Usual Care Group conditions: Pediatric Cancer conditions: Financial Stress conditions: Financial Hardship conditions: Disparities studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: SUPPORTIVE_CARE masking: NONE count: 40 type: ESTIMATED name: PediRISE Resource Program measure: Rate of Participant Consent measure: 6-Month Follow Up Rate for PediRISE Program Group measure: 6-Month Follow Up Rate for Usual Care Group sex: ALL maximumAge: 17 Years stdAges: CHILD facility: Boston Children's Hospital city: Boston state: Massachusetts zip: 02215 country: United States name: Kira Bona, MD, MPH role: CONTACT phone: 617-632-4688 email: Kira_Bona@dfci.harvard.edu name: Kira Bona, MD, MPH role: PRINCIPAL_INVESTIGATOR lat: 42.35843 lon: -71.05977 facility: Dana Farber Cancer Institute city: Boston state: Massachusetts zip: 02215 country: United States name: Kira Bona, MD, MPH role: CONTACT phone: 617-632-4688 email: Kira_Bona@dfci.harvard.edu name: Kira Bona, MD, MPH role: PRINCIPAL_INVESTIGATOR lat: 42.35843 lon: -71.05977 hasResults: False
nctId: NCT06283238 id: Pro00115121 briefTitle: Biobanking Upper Gastrointestinal Tumors to Evaluate Response (BURGER With BACON) overallStatus: NOT_YET_RECRUITING date: 2024-04-25 date: 2026-03-25 date: 2027-03-25 date: 2024-02-28 date: 2024-02-28 name: Duke University class: OTHER briefSummary: The goal of this observational study is to examine genetic changes that may contribute to immunotherapy resistance in gastroesophageal cancer. This information can potentially lead to the identification of new immunotherapeutic targets as well as improve the ability to identify those patients more likely to respond to immunotherapy.
* for blood, archived tumor tissue, and fresh tumor tissue Researchers will compare participants who are not getting immunotherapy to identify potential differences in expression levels of a gene. conditions: GastroEsophageal Cancer studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: OTHER count: 500 type: ESTIMATED name: Immune checkpoint inhibitor (ICI) or chemotherapy alone measure: Number of participants with Complete Response (CR) measure: Number of participants with Partial Response (PR) measure: Number of participants with Stable Disease measure: Number of participants with Progressive Disease sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Duke University city: Durham state: North Carolina zip: 27710 country: United States lat: 35.99403 lon: -78.89862 hasResults: False
nctId: NCT06283225 id: RCT004_PilotPia briefTitle: Pilot Study to Investigate the Effect of a Dysmenorrhoea App overallStatus: NOT_YET_RECRUITING date: 2024-02 date: 2024-07 date: 2024-07 date: 2024-02-28 date: 2024-03-01 name: Endo Health GmbH class: INDUSTRY briefSummary: The pilot study investigates the influence of a dysmenorrhoea app on the quality of life and symptoms of women with dysmenorrhoea. The intervention group can use the app over the study period of 12 weeks in addition to usual care, while the control group only receives the usual standard care. The aim is to evaluate the effectiveness of the app and to gain insights for the design of future studies. The study is expected to last seven months and include 100-200 participants. conditions: Dysmenorrhea studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: intervention group and control group primaryPurpose: SUPPORTIVE_CARE masking: DOUBLE whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 100 type: ESTIMATED name: Pia-App measure: Dysmenorrhea Symptom Interference Scale (DSI) measure: Moos Menstrual Distress Questionnaire, Form C (MDQ) measure: Visual analog scale (VAS) measure: Depression Anxiety Stress Scale mit 21 Items (DASS-21) measure: German Version of Pain Self-Efficacy Questionnaire (FESS) measure: Fatigue Severity Scale (FSS) measure: Pain Disability Index (PDI) sex: FEMALE minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06283212 id: ETX-DS-005 briefTitle: A Clinical Study to Evaluate the Safety and Efficacy of ETX101, an AAV9-Delivered Gene Therapy in Children With SCN1A-positive Dravet Syndrome acronym: UK Only overallStatus: RECRUITING date: 2024-04 date: 2029-12 date: 2029-12 date: 2024-02-28 date: 2024-04-17 name: Encoded Therapeutics class: INDUSTRY briefSummary: EXPEDITION is a Phase 1/2 study in the UK to evaluate the safety and efficacy of ETX101 in participants with SCN1A-positive Dravet Syndrome aged 6 to \< 48 months. The study follows and open-label, dose-escalation design. conditions: Dravet Syndrome studyType: INTERVENTIONAL phases: PHASE1 phases: PHASE2 allocation: NON_RANDOMIZED interventionModel: SEQUENTIAL primaryPurpose: TREATMENT masking: NONE count: 4 type: ESTIMATED name: ETX101 measure: Proportions of participants experiencing any treatment-emergent adverse events (AEs), serious adverse events (SAEs), related AEs, AEs with severity Grade ≥ 3, AEs resulting in study discontinuation, and AEs with fatal outcome. measure: Change from baseline in the standard score of the Vineland Adaptive Behavior Scales - Third Edition Adaptive Behavior Composite at Week 52. measure: Percent change in monthly countable seizure frequency (MCSF) to Week 52, with countable seizures defined as generalized tonic-clonic/clonic, focal motor with clearly observable clinical signs, tonic bilateral, and atonic seizures. measure: Change from baseline in the raw score of the Bayley Scales of Infant and Toddler Development® 4th Edition receptive language sub-domain at Week 52. sex: ALL minimumAge: 6 Months maximumAge: 47 Months stdAges: CHILD facility: Queen Elizabeth Hospital status: RECRUITING city: Glasgow zip: G51 4TF country: United Kingdom name: Patricia Clark role: CONTACT phone: 0141 232 7600 email: Patricia.Clark2@ggc.scot.nhs.uk lat: 55.86515 lon: -4.25763 facility: Great Ormond Street Hospital status: NOT_YET_RECRUITING city: London zip: WC1N3JH country: United Kingdom name: Helen Cross, MD role: CONTACT email: helen.cross10@nhs.net lat: 51.50853 lon: -0.12574 facility: Sheffield Children's Hospital status: NOT_YET_RECRUITING city: Sheffield zip: S10 2TH country: United Kingdom name: Research Team role: CONTACT email: research.sheffchild@nhs.net lat: 53.38297 lon: -1.4659 hasResults: False
nctId: NCT06283199 id: ORL-ORT-025 briefTitle: Comparing Reports Recorded by the Patients at the Time at Which They Feels Pain to What Patients Report at Monthly Visits to Assess Symptoms of Musculoskeletal Diseases. overallStatus: RECRUITING date: 2021-04-06 date: 2027-12-31 date: 2027-12-31 date: 2024-02-28 date: 2024-03-01 name: Ente Ospedaliero Cantonale, Bellinzona class: OTHER briefSummary: Patients will be introduced to the use of a mobile application for their smartphone to record the Ecological Momentary Assessment (EMA). This app will ask the patients to assess their pain and function two times daily for 2 months.
After 1 month and at the end of the 2 months, follow-up visits will be performed and patients will be asked to retrospectively evaluate the pain that they suffered and the level of function they had during the last month. conditions: Musculoskeletal Pain studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 1500 type: ESTIMATED measure: Difference in pain level sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: IRCCS Istituto Ortopedico Rizzoli status: RECRUITING city: Bologna country: Italy name: Alessandro Di Martino, MD role: CONTACT phone: 0039 051 6366567 email: alessandro.dimartino@ior.it lat: 44.49381 lon: 11.33875 facility: EOC - Orthopaedics and Traumatology Service status: RECRUITING city: Lugano zip: 6900 country: Switzerland name: Christian Candrian, Prof.Dr.med role: CONTACT phone: +41 (0) 91 811 61 23 email: christian.candrian@eoc.ch lat: 46.01008 lon: 8.96004 hasResults: False